A 2027 rebound with a CMS cloud
- The main thesis is a 2027 recovery after a hard 2025 and a 2026 reset year.
- Management raised 2026 adjusted EPS guidance to at least $26.75 after Q1, but the cleaner 2027 base is $25.75 after a one-time gain.
- Medicare Advantage membership fell 15.8% year over year to 1.9 million in Q1 2026 as Elevance cut less profitable plans.
- Medicaid membership was 8.5 million in Q1 2026, and management still expects a trough margin of -1.75% this year.
- The big new issue is CMS risk adjustment compliance, tied to a $935 million accrual and a July 31, 2026 deadline.
The rebound needs clean execution
Elevance is now a 2027 recovery story. The company had to reset earnings in 2025 because medical costs rose faster than expected in ACA and Medicaid. Management now calls 2026 a year of execution and repositioning, which means the company is shrinking weak business, raising prices where it can, and trying to rebuild margins.
The bull case is simple. The Medicare Advantage pullback is painful but planned, and management says it is still on track for a 2% margin in 2026. Medicaid is expected to bottom at a -1.75% margin. If those targets hold, Carelon can help push adjusted EPS growth to at least 12% in 2027 from a $25.75 baseline.
The bear case is also clear. CMS has notified Elevance that it intends to impose intermediate sanctions tied to historical Medicare Advantage risk adjustment data. Elevance recorded a $935 million accrual, but the final cost and business impact are still open questions. If sanctions happen, the Medicare Advantage recovery plan could take a real hit.
Finn's score fits that mixed setup. Elevance has decent financial health and a fair valuation score, but growth and recent performance are not strong yet. This is not a clean compounder right now. It is a repair story with a dated regulatory checkpoint.
Premiums first, Carelon as the flywheel
Most of Elevance's money starts with health insurance premiums. It covers Commercial, Medicare, and Medicaid members. The key job is pricing plans so premiums cover medical claims, while still staying competitive. If claims rise faster than prices, margins fall quickly.
Carelon is the second engine. CarelonRx manages pharmacy benefits, specialty pharmacy, formularies, rebates, claims, and home delivery. Carelon Services adds clinical and operating services such as behavioral health and home and community-based care. These services support Elevance's own insurance plans and also serve outside customers.
This structure can work well when the parts help each other. Carelon can lower costs for the insurance side and earn service revenue at the same time. The weak spot is that Carelon still feels pressure when Elevance's own health plan membership falls. In Q1 2026, CarelonRx adjusted scripts declined 4.3% year over year, even as external PBM sales helped offset that pressure.
What Elevance sells
Commercial health plans
These include employer plans and individual ACA exchange plans. ACA has become a key risk area because member illness levels and medical costs rose across the market.
Medicaid managed care
Elevance manages care for low-income members through state Medicaid contracts. The issue is timing: state rates have lagged medical cost trends, so management expects a -1.75% trough margin in 2026.
Medicare Advantage
These plans serve seniors, including HMO and D-SNP products. Elevance is cutting less profitable membership, with Q1 2026 Medicare Advantage members down 15.8% year over year to 1.9 million.
CarelonRx
CarelonRx is Elevance's pharmacy benefit manager. It handles scripts, specialty pharmacy, rebates, networks, and related pharmacy services for Elevance plans and outside customers.
Carelon Services
Carelon Services provides care management, behavioral health, and home and community-based services. It is the services growth engine, though lower internal membership can slow reported growth.
Federal Employee Program and other benefits
Elevance also serves federal employee and ancillary benefit markets such as dental and vision. These add scale but are not the main swing factor in the 2027 recovery thesis.
Q1 2026 segment mix
Shares use Q1 2026 gross reportable segment operating revenue before eliminations and excluding Corporate & Other. Health Benefits is the largest segment, while CarelonRx and Carelon Services have meaningful internal revenue links to the insurance business.
What could break the rebound
CMS sanctions hit Medicare Advantage
High impact · Medium oddsCMS told Elevance it intends to impose intermediate sanctions tied to historical Medicare Advantage risk adjustment data. Elevance has until July 31, 2026 to complete required compliance steps. If sanctions are imposed, they could slow or damage the Medicare Advantage turnaround.
The $935 million accrual is too low
High impact · Medium oddsElevance recorded a $935 million accrual for the risk adjustment issue. That is management's current best estimate, not a final settlement. A larger final amount would hurt earnings and investor trust.
Medicaid rates keep lagging costs
High impact · Medium oddsMedicaid cost trends remain high because members are using more care and have higher acuity. Management expects 2026 to be the trough year with a -1.75% margin. If state rate updates do not catch up, the 2027 recovery could slip.
ACA medical costs stay too high
Medium impact · Medium oddsACA profitability worsened after membership shifts and lower effectuation rates changed the risk pool. Elevance can raise prices, but regulators, competitors, and customer behavior limit how fast it can react. If healthier members leave, the risk pool can get worse.
Carelon cannot offset shrinking membership
Medium impact · Medium oddsCarelon is central to the growth story, but it still depends partly on Elevance's own health plan members. Q1 2026 showed that link, with CarelonRx adjusted scripts down 4.3% year over year. External wins need to be large enough to offset internal pressure.